High-dose chemotherapy with stem-cell support had as its basis the observation of dose-response relationships for many chemotherapeutic agents in laboratory models. The rationale to explore high-dose treatment in the clinic was further enhanced by several retrospective reviews in the 1980s which suggested delivered dose intensity of treatment was an important determinant of patient outcome. The availability of hematopoietic growth factors and technologic advances in the efficiency of stem-cell collection and administration have made the evaluation of exploring high-dose therapy safe and feasible. However, real questions remain regarding the apparently superior results of this treatment in the management of solid tumors. This paper reviews the results of high-dose chemotherapy in breast, ovarian and small cell lung cancers. Firstly the evidence for a dose-response relationship to chemotherapeutic agents in the 'standard' dosage range is examined. Secondly results of non-randomized and, where available, randomized trials of high-dose chemotherapy (HDCT) with stem-cell support are summarized and finally conclusions regarding the weight of the evidence for use of HDCT as 'standard' treatment are given. In none of these tumors is there sufficient evidence from randomized trials to consider HDCT a standard to be offered to all patients with a given stage of disease. The apparent benefit of HDCT seen in phase II trials could well be explained by such phenomena as stage shifts and patient selection. Many randomized trials in ovary and breast cancer are either ongoing or presented only as abstracts so final results must be awaited to quantify the benefit, if any of HDCT. It is acknowledged, however, that some practitioners already utilize this treatment. We speculate about the differences in philosophical approaches to cancer treatment which might contribute to early acceptance of novel therapies in the absence of adequate randomized data.
Introduction
Recommended dose, toxicity, and response rates of promising new agents or therapies in cancer treatment are evaluated first in phase I and II clinical trials. In rare cases the benefit of a therapy is so obvious that further testing is not necessary and would serve only to deny patients access to a potentially curative treatment. Unfortunately, the benefit of most drug therapies on important clinical outcomes in oncology are not as striking, and therefore not as clear cut. In uncontrolled studies, results are influenced not only by chance, but also by biases in patient selection or other unknown factors.
When one therapy appears to be superior to another on the basis of historical comparison, evidence based medicine suggests that claims of improved efficacy need to be backed up by randomized controlled clinical trials, before it is widely adopted [1] . By this means, one hopes to avoid biases and systematic errors that can occur when comparing two treatments, increasing the validity of a trial by ensuring an equal distribution of all determinants of outcome [2] . High-dose chemotherapy (HDCT) with autologous stem-cell rescue for solid tumors has not followed the path described above. Although very few randomized trials have been completed, in some areas HDCT is considered standard in certain tumor types. The competing philosophies behind the high-dose concept, as well as perspectives on currently available data will be reviewed with the aim of addressing the question 'should high-dose chemotherapy with stem-cell rescue be considered standard in selected solid tumors based on current knowledge'? For the purposes of this paper we define HDCT as treatment given in sufficiently high doses to require rescue with either bone marrow or peripheral blood stem cells.
Why the debate?
The importance of discussing this issue at the present time is underscored by the large volume of transplants occurring outside the research setting. Antman et al. have reviewed the trends in HDCT with stem-cell support for breast cancer from 1989 to 1995 using the Autologous Blood and Transplant Registry [3] . This extensive registry captures data on autotransplants done for all diseases from Central and South America and up to 50% of those performed in North America. During this interval (1989) (1990) (1991) (1992) (1993) (1994) (1995) , 19 ,291 patients received HDCT with autologous stem-cell support. Thirty-one percent (5886) of these patients had breast cancer. HDCT for breast cancer has increased significantly over time, rising from 16% of all transplants done in 1989 to over 40% in 1995. In 1993-1994 breast cancer was the most common indication for stem-cell transplant of all types. Despite these high figures only 11% of high-risk primary breast cancer patients and fewer than 1% of those with metastatic disease were treated as part of a randomized cooperative group trial. Why so few have participated in randomized trials may be attributable to the varying philosophies of treating physicians as well as differing patient expectations regarding treatment benefit.
It seems reasonable to postulate that the amount of evidence any given physician needs to change practice may be related to his/her pre-existing views of cancer biology and treatment and whether they might be considered to fall into the hypothetical categories of fatalists or interventionists. 'Fatalists' can be defined as those who believe the patient and his/her tumor are the most important determinants of individual outcome. Believing this, they would require strong evidence to change practice (especially if a new treatment carried with it serious morbidity). In contrast, 'interventionists' can be portrayed as those who believe the treatment they recommend is the most important factor in individual patient outcome. Having this belief, they would be eager to embrace novel therapies on the basis of promising phase II results. Although portrayed as extremes for the purpose of argument, in fact there is undoubtedly a continuum along this axis of philosophic views leading to different thresholds under which individual physicians will adopt new therapies.
What should drive a change of practice?
Significant changes in practice should be grounded in sound evidence. Several factors are of importance to consider with respect to adopting any new approach. First of all, there should be a sound rationale for the proposed new treatment. Secondly, the nature and strength of the evidence should be sufficiently robust that results cannot be explained by chance or selection biases (phase II vs. phase III). Thirdly, the goal of therapy with respect to benefit (e.g., overall survival, disease-free survival, quality of life, economics) should be clearly stated. Consideration must be given to the magnitude of benefit which would be required before considering a new treatment worth adopting when balanced against its observed toxic effects. Finally, before considering a new therapy 'standard' we must consider whether it is truly available to all who might benefit not only in terms of expertise in delivery but also in terms of it's financial burden. To a certain extent all these elements play a role in determining whether new treatments can become 'standard' therapy. In this review we consider the scientific rationale and clinical evidence which exists regarding the benefits of HDCT. We have not attempted to define cost/benefit ratios nor to assess the economic aspects of this treatment.
When might high-dose chemotherapy in solid tumors be expected to work?
It is postulated that, in order to achieve a cure for a particular tumor, a chemotherapeutic agent should demonstrate a constant fractional cell kill for each proportional increase in drug dose. This is represented as a steep linear dose response curve plotted on a logarithmic scale [4] . Intrinsic or acquired tumor resistance is believed to be one of the most important elements affecting response and the ability to achieve a cure. The interaction between tumor sensitivity and resistance is unfortunately seen all too frequently in breast, ovary and small-cell lung cancer where high initial response rates to chemotherapy are seen, only to be followed by subsequent relapse and resistance to further treatment. Proponents of HDCT feel this resistance can in part be overcome by increasing the dose of certain chemotherapeutic agents. If this is true, then tumors fitting this model should at least demonstrate dose-response behaviour to active drugs given in the conventional dose range. In addition, the drugs eliciting this affect should be appropriate for further dose escalation with dose limiting toxicity (DLT) primarily due to myelosuppression allowing rescue with peripheral blood stem cells (PBSCs). Ideally their non-hematologic effects should be limited and both short and long-term morbidity and mortality should be minimal. Inherent in this approach is the underlying belief that resistance in these tumors can be overcome with the relative dose increase which can be achieved with PBSC support. We will now consider breast, ovary and lung cancer in the context of evidence of a dose response effect, and examine currently available high-dose trials, both randomized and nonrandomized.
Breast cancer (metastatic)

Retrospective studies
In 1984, Hryniuk et al. conducted a retrospective study examining whether the dose intensity (drug delivered as mg/m 2 /wk) of CMFand FAC containing chemotherapy regimens was an important determinant of outcome in terms of response rate and median survival, in patients with metastatic breast cancer [5] . He concluded that dose intensity was important for optimal tumor response and patient survival. These results have been criticized both for the methodology of the study (i.e., including nonrandomized trials in the analysis) and the assumptions regarding drug delivery (i.e., that all drugs in a combination regimen contribute equally to outcome). As this was an hypothesis generating study, the results needed prospective confirmation. Tannock [6] Engelsman [7] Bastholt [8] Habeshaw [12] Carmo-Pereira [14] Hortobagyi [13] Focan [9] Brufman [10] French Group [11] Nabholtz [15] Regimens Abbreviations: C -cyclophosphamide; M -methotrexate; F -5-rlurouracil; E -epirubicin; A -adriamycin; Tx -paclitaxel; RR -response rate; MS -median survival. a />-value <0.05.
Randomized trials at standard doses in metastatic breast cancer
Numerous randomized trials in patients with metastatic breast cancer have since been published examining whether the dose intensity achievable without PBSC support can alter outcome, with a few important studies presented in Table 1 . With respect to alkylating based regimens, Tannock et al. compared conventional dose IV CMF in patients with metastatic breast cancer, to the same regimen with all the drugs given at half the dose. An increased response rate of borderline significance (26% vs. 11%, P -0.06) and a trend for increased survival in the higher dose arm (15.6 months vs. 12.8 months) was seen [6] . Although more toxicity was experienced in the higher dose arm, this was offset by an improved quality of life with respect to disease related symptoms. When classical oral CMF was compared to IV CMF in a similar patient population, a significant improvement in response (48% vs. 29%, P = 0.003) and median survival (17 months vs. 12 months, P = 0.016) was noted for the oral CMF arm [7] . This difference in outcome has been attributed by the authors to the ability to deliver a higher dose intensity of all drugs with the oral regimen. It is important to note that the higher dose arm in both of these studies is more in keeping with what would be considered 'standard dose' therapy. These results would seem to support the idea of a dose threshold below which patients may experience inferior outcomes. Whether outcome can be improved above this level was not addressed by these studies.
Anthracyclines (doxorubicin-epirubicin) have also been examined in the randomized setting both as single agents and in combination regimens. In some of these trials dose intensity was doubled beyond what would now be considered standard. As shown in Table 1 , several studies have shown significant improvements in response rate without any change in overall survival [8] [9] [10] [11] [12] , while another trial showed no effect on response or survival [13] . A study by Carmo-Pereira showed an increase in both response rate and survival for single-agent doxorubicin [14] . These results suggest that doubling anthracycline dose intensity produces a modest dose effect for response which seldom translates into a survival benefit. Even for newer agents such as paclitaxel, increasing the dose did not produce significant increases in either response or survival, although there was a trend for a dose effect [15] . Several comments can be made at this point. It is possible the major resistance mechanisms in metastatic breast cancer in the clinical setting cannot be totally overcome by augmenting the dose of currently available drugs. Tumor factors such as tumor cell kinetics, tumor size, tumor cell heterogeneity and duration of tumor growth, as well as drug features such as dose, schedule and delivery likely all contribute to varying extents to determine the outcome of a particular treatment and the shape of the dose response curve [16] . Alternatively it can be argued that dose increases may overcome resistance but simply doubling the dose intensity, as was done in most of these studies, is not enough. More substantial increases in dose might be necessary before survival of metastatic breast cancer is affected. Furthermore, increasing the dose by only one to two times may not be enough to overcome any difference in individual pharmacokinetics that may be masking the true effect of dose escalation [17] . The only way to achieve significant dose escalation then is through HDCT with marrow support.
The appropriate agents for dose escalation
Alkylating agents including platinum compounds are felt to be the most appropriate agents for dose escalation for a number of reasons [4] . There is evidence from some breast cancer cell lines and animal tumor models for the existence of a steep dose response curve for these compounds. In vitro evidence demonstrating synergism between alkylating agents and lack of cross resistance adds to their benefit by allowing them to be used in combination [4] . Low levels of resistance have been overcome by only a 5-to 10-fold increase in dose. Their dose limiting toxicity is primarily hematologic, and non-hematologic toxicities at high doses tend to be non-overlapping. Unfortunately, with the possible exception of mitoxantrone, agents from the anthracycline class, are not suitable for substantial dose escalation because of their cardiac and mucosal toxicities. The antimetabolites and vinca alkaloids are also generally not suitable agents for high-dose therapy because not only does non-marrow toxicity limit significant escalation but they have also shown very shallow dose response curves both in vitro and in vivo [4] .
Trials of high-dose therapy in metastatic breast cancer
Since the early 1980s, numerous phase I and II trials have been completed in metastatic breast cancer employing HDCT with bone marrow or stem-cell support [reviewed in 17] . Early trials were conducted in patients with advanced resistant disease. Use of single agent alkylators in high doses resulted in overall response rates of 41% with complete response rates (CR) of 11% [4, 18] . Combination HDCT produced more promising response rates (88% RR, 37% CR), and response durations, however, median survival was still short (five and eight months) and there was significant associated toxicity [19, 20] . Treatment related mortality was as high as 18% [19] . These early phase I and II studies demonstrated a possible relationship between increased dose and improved response rate, however a survival benefit was not apparent. Following the lessons learned from leukemia studies, that high-dose treatment in an earlier chemosensitive state was essential for a survival benefit, phase II trials in metastatic breast cancer were then conducted using HDCT as first line treatment in what was expected to be less resistant disease [21] . In a study by Peters et al. one cycle consisting of cyclophosphamide 1875 mg/m 2 daily x 3, cisplatin 55 mg/m 2 daily for 72 hours and carmustine 600 mg/m 2 for one day was given to patients with estrogen receptor negative (ER-) metastatic breast cancer and no prior chemotherapy for their advanced disease. Response rates remained good (77% RR, 54% CR), but median survival (10 months) was not improved and mortality was still unacceptably high at 22.7% [22] . Some important observations, however, were made from this study. Relapses tended to occur at sites of bulky disease and two patients in this study remained in unmaintained CR at 2.5 years after treatment. So it appeared that less bulky disease and attainment of a complete response were important for improving outcome, which was a similar finding in non Hodgkins lymphoma. Therefore future studies were designed to administer HDCT to patients who had had the bulk of disease reduced by conventional dose induction chemotherapy regimens. The trend for treating earlier chemosensitive disease, improvements in supportive care and the technologic advances in transplant therapy (peripheral blood stem cells and growth factors) have all likely contributed to the reduction in mortality from the procedure which had decreased to less than 5% by 1995 [3] . The more recent studies employing HDCT with stem-cell rescue in patients achieving a complete or partial response to conventional dose induction regimens have reported long-term progression free survival rates of 20% at two to three years [23] [24] [25] . While CR rates are increased an additional 10%-26% with highdose therapy, how this contributes to outcome is unclear. In a study by Antman et al. [23] , high-dose CTCb (cyclophosphamide 1.5 gm/m 2 /d, thiotepa 125 mg/m 2 /d and carboplatin 200 mg/m 2 /d given as a continuous infusion over 96 hours) was administered to patients with metastatic/Iocally advanced breast cancer responding (at least PR) to conventional dose standard regimens. This study found that it was mainly those achieving a CR to induction chemotherapy who survived the longest after HDCT, while those who converted from a PR to CR with HDCT survived no longer than those obtaining only a PR as the final response (six months median survival). The exceptions were PR patients having only bone metastasis who lived as long as patients with CR, which would not be unexpected for primarily bony disease. In another trial by Williams et al., however, even PR patients converting to CR had prolonged survival [25] . In the Peters study described above, one patient who did not even respond to high-dose therapy lived progression-free for one year [22] . These conflicting reports demonstrate the complex and heterogenous nature of breast cancer. Without performing randomized studies it is difficult to determine whether the favourable results obtained in these high-dose phase II trials is due to selection bias or treatment related factors.
Evidence from the literature strongly supports the need to compare conventional dose chemotherapy to HDCT in a randomized setting. The group at MD Anderson reported the long-term outcome of patients with metastatic breast cancer treated at their centre, on various trials of conventional dose doxorubicin containing regimens from 1972-1983 who obtained a complete remission to treatment [26] . Of 1581 patients, 263 patients (16.6%) achieved a CR. At five years 3.1% of the total patient population or 18.6% of all CRs had remained in unmaintained CR. At 10 years 1.6% of all patients or 9.8% of CRs were still in unmaintained CR. The median progression-free survival for the patients with CR was 22 months and median survival was 42 months. The CR patients achieving such long-term survival had a median age of 50, had dominant visceral disease, fewer metastatic sites (usually 1) and a better performance status. Only 0.5% of patients with PR and 0.5% of those with no change in their disease remained progression-free for five years. This same group from M.D. Anderson also published a report looking at the outcome of a similar group of patients treated with only conventional-dose anthracyline containing regimens who would have been eligible for HDCT versus those who not be eligible because of specific entrance criteria [27] . Only 40% of all patients from these studies would be eligible for HDCT. Even though they did not receive HDCT, the HDCT candidates had significantly higher response rates (CR: 29.6% vs. 7.7%), disease free survival (median: 16 months vs. 8 months), and median survival (30 months vs. 17 months, respectively) compared to non-candidates. Even when the eligible responders were compared to non-eligible responders the differences in survival were still significant. These reports confirm that there are long-term survivors with conventional dose chemotherapy regimens, and that patient selection may be playing a greater role than suspected in the favourable results obtained with the phase II HDCT trials.
The only fully published randomized trial in metastatic breast cancer did not utilize the treatment approach of intensification for responders. Bezwoda et al. compared either two cycles of high-dose CNV (cyclophosphamide, mitoxantrone and VP-16) with PBSC support, to six to eight cycles of conventional-dose CNV (replacing VP-16 with vincristine) [28] . Responders were then placed on tamoxifen at the completion of chemotherapy. The dose intensity achievable with this regimen resulted in a four-fold increase in cyclophosphamide and a 2.2-fold increase in mitoxantrone. A significant improvement in response rate of 95% (51% CR, 44% PR) was seen for the HD-CNV arm compared to 53% (4% CR, 49% PR) for the LD-CNV arm, and a doubling of median survival from 45 to 90 weeks in favour of the high-dose arm. There have been several criticisms of this study. Patient numbers were small (45 in each arm), there was an imbalance in post chemotherapy treatment with more patients on the high-dose arm receiving tamoxifen, and results of the low-dose arm seemed inferior to an earlier trial of the same drugs [29] .
There are three additional randomized trials of HDCT in metastatic breast cancer reported in abstract form. In the first study, all patients were treated up front with conventional dose AFM (doxorubicin, 5-fluorouracil and methotrexate) [30] . Those achieving a CR were then randomized to delayed vs. immediate high-dose consolidation with cyclophosphamide, cisplatin and carmustine (CBP) and autologous bone marrow support (ABMS). Patients in the delayed arm who relapsed were treated with the same high-dose regimen. Disease free survival was superior in the immediate transplant arm compared to the delayed arm (0.9 year vs. 0.3 year). Unexpectedly, however, overall survival was superior (median: 3.2 years) when transplant was delayed vs. receiving high-dose therapy initially (median 1.9 years). The fact there is no control arm of conventional dose treatment is a major criticism of this study. However these results raise the issue of the potential importance of scheduling of HDCT as a factor in determining outcome.
The second study (the Philadelphia Intergroup Study) was reported at the American Society of Clinical Oncology meetings in May 1999. This trial randomized 199 metastatic breast cancer patients who had responded to induction CMF or CAF chemotherapy to receive consolidation HDCT (cyclophosphamide 1200 mg/m 2 /day, thiotepa 125 mg/m 2 /day and carboplatin 200 mg/m 2 /day as a continuous infusion for four days) or conventionaldose maintenance CMF [31] . With a median follow-up of 31 months there were no significant differences in overall survival or toxicity between the groups. The study has been criticized because, of the 303 patients responding to induction treatment (553 were registered at start of induction treatment), only 199 were randomized. However, the comparison between groups in the randomized cohort remains valid. There has also been concern expressed that the 'standard' arm of continuous CMF is not really standard practice and that the high-dose arm was not aggressive enough. The evidence cited for the latter is the low conversion rate of PR to CR seen in that arm and the very low transplant mortality. Nonetheless, these criticisms cannot explain away the failure to observe any survival advantage (or even a trend to a survival advantage) in the high-dose arm.
The third study, PEGASE 04, was a small randomized trial of high-dose chemotherapy (mitoxantrone, cyclophosphamide, melphalan) compared to conventional chemotherapy in 61 women who had responded to 4-6 cycles of induction treatment [32] . After five years of follow-up, there was no statistically significant difference in progression-free and overall survival between the arms. The standard-and high-dose arms showed relapse rates of 90.8% and 90.7%, respectively. Survival rates were 18.5% and 29.8%. The sample size of this trial was small and so not well powered to detect differences in the 10%-20% range.
Based on the data presented so far can we accept HDCT as standard therapy for metastatic breast cancer? It would seem the answer is no. The findings of the Philadelphia and French studies serve to emphasize that HDCT should not be given as standard practice. It is possible that a select subset of patients may indeed benefit from high-dose therapy, whether it be in the form of improved disease free survival or an actual increase in overall survival. However, this has not yet been shown in a definitive fashion. This is even more important when one considers potential unknown complications of treatment. In addition to acute morbidity of HDCT, recently van Dam et al. noted that women who had undergone high-dose chemotherapy for early stage breast cancer had a greater impairment of cognitive function compared to those receiving conventional chemotherapy [33] . There remain a number of ongoing randomized trials (Table 2 ) comparing HDCT to standard treatment in metastatic breast cancer which will add further information about the benefit, if any, of HDCT in recurrent disease and which may resolved the apparent contradiction between the Bezwoda data and those of the other two trials. There is no need to initiate new studies until the results of those ongoing are known. The only question which might need to be addressed is the importance of initial HDCT (rather than consolidation) which, aside from the work of Bezwoda, has not been studied in metastatic disease.
Breast cancer (primary)
Retospective analysis
Following the 1984 analysis suggesting a relationship between the dose intensity of received chemotherapy and outcome in metastatic breast cancer, Hryniuk et al. conducted a similar review in 1986 of adjuvant chemotherapy for stage II breast cancer [34] . This retrospective analysis, which included randomized adjuvant trials of CMF or CAF containing regimens, demonstrated that relapse free survival was significantly improved for those receiving a higher projected dose intensity (data on received DI was not recorded by most studies). All patient groups in the analysis appeared to benefit (pre/ postmenopausal and 1-3 and > 3 lymph nodes). The slope of the curve for three-year RFS vs. relative DI for those with one to three involved nodes was steep initially and then plateaued while the slope for those with > 3 LN remained steep but with considerable scatter. The reasons for the difference in curves is not clear, however the first curve would suggest that increasing the DI beyond a certain level does not lead to further benefit. In order to prospectively evaluate this hypothesis, several randomized trials have been conducted.
Randomized trials in primary breast cancer at 'standard' doses
Some of the larger trials designed specifically to answer the question of dose intensity will be reviewed. Three of these studies are presented in Table 3 . A trial by the CALGB varied all three drugs in the combination regimen of CAF to assess whether increases in total dose or dose intensity result in improved disease free and overall survival for stage II breast cancer patients [35] . Significant decreases in these outcome measures were seen when patients received 50% less (group 3) of the total dose and DI of the highest dose arm (group 1), whereas there were no significant differences in outcome for a 30% reduction in DI (group 2) compared to group 1 when total dose was constant. These results appear to support the concept of a threshold dose/dose intensity which is necessary to achieve optimal results. Since there was no difference in outcome between the high and intermediate dose intensity groups, this would seem to indicate that even higher doses would not produce an enhanced effect. Importantly, patients in the higher intensity groups (group 1 and 2) experienced more toxicity. Two studies have examined doubling the dose beyond what is considered 'standard'. When FEC50 was compared to the same regimen but with doubling of the epirubicin dose to 100 mg/m 2 in node positive patients, DFS at a median of 30 months was significantly increased (62.1% vs. 70.5%) with no improvement in three-year overall survival [36] . A three-arm trial conducted by the NSABP varied the dose and dose intensity of cyclophosphamide in the combination regimen of doxorubicin and cyclophosphamide [37] . No difference in either DFS or OS was seen in any of the arms with either a doubling of DI or doubling of both DI and total dose of cyclophosphamide. These trials seem to point to similar conclusions as were derived in the metastatic setting: that is, there appears to be a threshold dose in the conventional range which is required to obtain optimal results. Escalation beyond this level by doubling the dose or dose intensity does not seem to improve Table 3 . Randomized trials in primary breast cancer examining the effect of increasing dose/dose intensity of conventional adjuvant chemotherapy regimens on disease-free and median survival.
Author [reference]
Wood [35] Bonneterre [36] Fisher [37] Arms CAF 300/30/300 CAF 400/40/400 CAF 600/60/600 FEC 500/50/500 FEC 500/100/500 outcome. Whether further escalation is likely to improve outcome depends on the characteristics of the doseresponse curve for this tumor with these drugs. The data suggest the slope of the curve is shallow. However, in support of the high-dose concept, in vitro studies indicate that in order to eradicate both sensitive and resistant cells, a five to 10-fold increase in dose of a single alkylating agent is needed to produce the log cell kill necessary to achieve a cure [4] . Five-six-fold increases are achievable with single-agent alkylators, and when used in combination it is postulated that the amount of log cell kill necessary for cure could be obtained [4] . So it may not be until doses are increased to this extent that an impact on outcome may be expected.
High-dose trials in primary breast cancer
High-dose chemotherapy has also been undertaken in phase II trials in high-risk primary breast cancer (massive axillary nodal involvement, inflammatory and locally advanced cancers) where despite current treatments there is still a high rate of relapse and death [20, 21] . There have been many phase I and II studies with a few reporting long-term results. Much of the work has been done in those with a high number of involved axillary lymph nodes, with fewer trials in locally advanced and inflammatory breast cancers.
Long-term follow-up studies of breast cancer patients treated only with local modalities (e.g., mastectomy) have demonstrated that those with > 10 positive axillary lymph nodes achieve five-year disease-free and overall survival rates of approximately 30% and 50% [38, 39] . It is also recognized that as the number of involved lymph nodes increases the prognosis continues to worsens. When treated in the adjuvant setting with an anthracycline containing regimen, five-year disease-free and overall survival results of 36%-41% and 54%-58%, respectively, have been achieved, representing a slight improvement in outcome [37, 40] . In a study by Peters et al. using HDCT in 85 patients with 10 to greater than 20 positive axillary lymph nodes a survival estimate of 79% and an event-free survival rate of 72% was seen at 2.5 years of follow-up. Therapy consisted of four cycles of standard-dose CAF followed by one cycle of highdose cyclophosphamide, cisplatin and carmustine and then loco-regional radiotherapy [41] . The probability of relapse was less, and the event free survival was superior for those treated with HDCT compared to a group of historical controls from three other CALGB studies where standard doses of CMFVP+/-VATH or CAF chemotherapy were used. Important differences between the historical comparison group and the high-dose group exist. In the standard-dose chemotherapy trials, the median age was higher, a larger proportion of patients had greater than 20 lymph nodes (20%-26% vs. 12%), a greater proportion of patients in the highdose group received local radiation, which may have had some impact on loco-regional control, and the intense staging for the high-dose trial (bilateral bone marrow examination) likely excluded a small proportion of patients with occult metastatic disease who may have a worse prognosis. Toxicity in the HDCT trial was considerable. Eleven percent of patients died from acute toxicity of the transplant. Long-term, 31% developed varying degrees of pulmonary toxicity (likely related to the locoregional radiation) and 8% developed HUS one to six months after high-dose treatment.
Another study by Gianni et al. reported a five-year projected relapse-free survival and overall survival rate of 57% and 70%, respectively, in high-risk patients with > 10 positive axillary lymph nodes receiving a sequential high-dose regimen [42] . Sixty-seven patients received treatment with high doses of cyclophosphamide, methotrexate plus vincristine, cisplatin and finally melphalan each given in a sequential manner followed by PBSC. Most patients also received loco-regional radiation. In an historical control group from the same institution, five-year relapse-free and overall survival rates were lower at 41% and 60%, respectively. Only one patient died during the high-dose treatment, and this event was thought to be related to toxicity from GM-CSF. Toxic effects included pneumonitis in 36% (related to radiation) and late herpes zoster in 30%.
The two trials described above contain the largest number of patients evaluated in single arm studies.
Several other phase II trials have reported similar DFS and OS results at three to five years follow-up [43] [44] [45] . There are many other phase II trials which have been completed to date [reviewed in 17, 20] . It is difficult to draw firm conclusions from these studies as few have reported long-term results. In addition, treatment regimens varied (different induction and HDCT regimens) and studies contained slightly different mixes of highrisk patients (> 10 LN, locally advanced and inflammatory). Noteworthy is the fact that treatment related mortality in these trials has decreased to 0%-2%.
Compared to historical controls, the results of HDCT in these high-risk primary breast cancer patients appears encouraging and the procedure now seems safe. However, as noted earlier in the context of metastatic disease studies, patient selection makes comparison of these data with historical series problematic. A recent retrospective analysis by Garcia-Carbonero et al. points to the importance of selection criteria in the outcome of such trials. They examined the outcome of high-risk breast cancer patients (>10 positive lymph nodes) treated with standard chemotherapy (CMF or anthracycline containing regimens) [46] . Out of 171 such highrisk patients, 74% were found to be 'eligible' for highdose therapy. Compared to non-eligible patients, median disease-free and overall survival were significantly better in HDCT candidates (who did not receive HDCT) with results of 26.4 months vs. 35.9 months and 42.7 months vs. 86.2 months, respectively. Another important factor which influences the outcome in these series is the stage migration which occurs with more intensive staging procedures. A group from The Toronto Hospital in Canada have shown that up to 23% of high-risk breast cancer patients have metastases detected by CT or bone marrow biopsy that would not be detected by routine screening by ultrasound, chest X-ray or bone scan [47] . These patients with occult metastases would normally not have been included in studies of HDCT, but would have been part of the historical series to which HDCT results are compared. Thus randomized data are necessary before such treatment becomes standard.
Several randomized trials are currently underway (Table 4) and recently five trials have been reported at the 1998 and 1999 meetings of the American Society of Clinical Oncology. Three of these studies compared HDCT to conventional-dose standard regimens, while the remaining two studies compared HDCT with stemcell support to intensive regimens supplemented with growth factors. In the first of these [48] 97 patients with extensive axillary node metastases who were stable or had responded to three cycles of FEC were randomized after surgery to receive one more cycle of FEC followed by radiation and tamoxifen or the same treatment plus high-dose cyclophosphamide, thiotepa and carboplatin with PBSC support. With a median follow-up of 49 months, the overall and relapse free survivals were 75% and 54%, with no significant differences noted between the treatment arms. In a second trial, 78 patients with > 4 involved nodes received either FAC x 8 cycles or the same treatment followed by HDCT with cyclophosphamide, etoposide, and cisplatin plus autologous stem-cell support [49] . Four-year disease-free and overall survival rates for the high-dose and low-dose groups were 48% vs. 55% and 60% vs. 68%, respectively. The third trial randomized 154 patients with adverse prognostic factors including 10 or more positive axillary nodes or with 7-9 nodes with large primary tumors. Patients received either up front high-dose CNV (cyclophosphamide, mitoxantrone and etoposide) or six cycles of CAF [50] . At a median follow-up of five years, there were significantly fewer relapses and deaths in the high-dose arm. Relapsefree survival (7.6 vs. 3.6 years; P < 0.05) and overall survival (7.6 vs. 6.1 years, P < 0.05) were also significantly improved in the high-dose compared to the standarddose arm.
In the other two trials, HDCT was compared to a more intensive chemotherapy regimen than might be considered standard. In the first of these Peters et al. randomized 783 patients with stage II or III A disease having ^ 10 positive lymph nodes to receive 4 cycles of CAF followed by either high-dose CPB (cyclophosphamide, cisplatin, BCNU) or intermediate-dose CPB supported by G-CSF [51] . Preliminary results were recently reported. At a median follow-up of 37 months, no significant differences between high-and intermediatedose arms were noted in relapse-free (68% vs. 64%, P = 0.7) or in overall survival (78% vs. 80%, P = 0.1). Twenty-nine patients in the high-dose arms died of treatment related toxicity vs. none in the intermediatedose arm. Follow-up is continuing but final results will not be available for some time. The final study was conducted by the Scandinavian Breast Cancer Study Group. In this trial researchers randomized 525 women with high-risk primary breast cancer to dose escalated tailored FEC therapy with supportive G-CSF vs. 3 cycles of FEC followed by high-dose CTCb (cyclophosphamide, thiotepa and carboplatin) with stem-cell support [52] . After a median 20 months of follow-up, 55 relapses and 15 deaths occurred with 'tailored' FEC therapy compared with 78 relapses and 25 deaths in the high-dose arm. There were eight patients who developed acute myeloid leukemia/myelodysplastic syndrome in the 'tailored' FEC arm. Two fatal outcomes were directly related to therapy in the high-dose arm. 1 The first three trials were small and both of the first two were underpowered to detect differences less than about 30% in the relapse free survival outcome. However, it is interesting to note that the observed differences in relapse free survival do not favour the high-dose arm in either the Rodenhuis or the Hortobagyi study. The third trial by Bezwoda showed significant improvement in both relapse free and overall survival. Neither of the last two trials showed an improvement in survival although it is worth noting that neither of the studies reported mature data, so continued follow-up may reveal later evidence of benefit. Furthermore, neither of these trials had 'standard' dose control arms so do not contribute to resolving the debate about standard vs. HDCT in this setting. Against this consideration is the fact that moderately intensified adjuvant therapy has not been shown to improve outcome over standard doses alone [35] [36] [37] , although those earlier studies did not use regimens identical to the intensified treatments in either the Peters or the Scandinavian trials. However one chooses to integrate the outcomes of these five studies, it can be concluded that HDCT should not be considered standard in high-risk adjuvant patients. The final results of these trials plus the results of ongoing trials listed in Table 4 will help to finally establish the magnitude of the benefit, if any, of this approach. One important factor which should be pondered is the potential value of immediate versus delayed (consolidation) use of high-dose treatment. It is interesting that the two studies (one in metastatic disease and one in adjuvant therapy) which are positive both used the strategy of initial HDCT. Although the consolidation approach has a logical basis extrapolated from experience in hematologic malignancies, it may be that the use of induction therapy in solid tumors merely permits the evolution of more drug resistance which late introduction of highdose treatment cannot overcome. With that in mind, it is useful to note that only the adjuvant Milan trial currently ongoing is designed to give high-dose therapy up front.
Patients with locally advanced and inflammatory breast cancer are variably included in high-dose trials. Inflammatory breast cancer, when treated with standard combined modality treatment, has reported five-year disease-free and overall survival results of 22%-54% and 30%-70% and a median survival of 25-56 months [53] . Response rates range from 41%-98% (7%-55% CR) with standard combination chemotherapy. So far only very early results are available from a few phase II trials incorporating high-dose therapy into a combined modality approach exclusively in inflammatory breast cancer. Two-year disease-free and overall survival results of 57%-70% and 80%, respectively, have been reported [54, 55] . Others with follow-up to 20 months (1.6 years) have obtained progression free survival rates of 78%-80% [56, 57] . These are very early results and longer follow-up is needed before any possible benefit can be determined.
Locally advanced breast cancer represents a very heterogenous group which includes both stage Ilia and Illb patients. Trials of high-dose therapy in this group include various mixtures of locally invasive tumors, massive axillary nodal involvement and inflammatory breast cancers with diverse prognosis making interpretation of results difficult. It is an important group to study because even with conventional combined modality treatments where local control, operability and diseasefree survival all seem better, five-year survival does not appear to be significantly improved and remains in the range of < 50% [58] .
In summary, although results from non-randomized trials appear encouraging for outcomes in high-risk primary breast cancer as well as locally advanced disease, randomized trials, particularly in high-risk primary disease, do not support its use as a standard. Further arguing against its routine use are issues of cost, availability, toxicity and the fact that some patients will have long-term survival with conventional dose treatments. The results of the ongoing randomized trials outlined in Table 4 will be crucial to determine the appropriate role of this treatment in the management of primary breast cancer.
Ovarian cancer
Ovarian cancer is another malignancy deemed to be a suitable candidate for trials of HDCT with stem-cell support. In advanced disease, response rates of 70-80% (clinical CR 30%-50%, pathologic CR 10%-30%) can be achieved with first line cisplatin containing chemotherapy. However, even in those who obtain a pathologic CR, 40%-60% will relapse and the 10-year survival of all patients is only 10%-20% [59] . Although responses are seen to second-line therapy, durable remissions are rare and relapsing patients eventually die of their disease. Thus this is another tumor which demonstrates high initial response rates to chemotherapy but also high relapse rates. As for many solid tumors, both intrinsic and acquired resistance to the most active agents (cisplatin, paclitaxel and other agents), impede the possibilities of cure or long-term survival.
In vitro and retrospective data
Several cellular mechanisms of resistance to cisplatin have been postulated in ovarian cancer, with most of them affecting the levels of active drug in the cell [60, 61] . The actual role these mechanisms play in clinical resistance is not yet fully understood. In vitro experiments have shown that increasing the dose of cisplatin by at least five times is one approach by which resistance, whatever the operative mechanism, can be overcome [62] . Because of this laboratory evidence of a doseresponse, many have attempted to overcome resistance in ovarian cancer clinically by augmentation of dose. Similar to the reports in both metastatic and primary breast cancer, Levine and Hryniuk demonstrated in a retrospective analysis that increases in the dose intensity of cisplatin were associated with increased response rate and survival [63, 64] . Interestingly, the 'plateau' on the dose-response curve from their retrospective review seems to appear at a relatively low-dose intensity of cisplatin 15 mg/m 2 /wk.
Randomized trials in ovarian cancer of 'standard'doses of chemotherapy
Several randomized trials have been completed examining the effect of increased platinum dose and/or dose intensity in ovarian cancer. The majority of studies have been negative but a few were positive contributing to controversy in this area and fuelling interest in HDCT studies. Some argue it is the total dose of platinum compound administered that is the most important determinant of outcome, while others believe dose intensity is the more important parameter. Eleven studies (Table 5) evaluating various combinations of increases in dose intensity or total dose of cisplatin (or carboplatin) have been evaluated in patients with advanced stage ovarian cancer. In general these studies were only able to achieve at most a doubling in either of these variables, with dose intensity of cisplatin ranging from 12.5 mg/m 2 /wk tõ 30 mg/m 2 /wk and total dose ranging between 300-600mg/m 2 .
Six studies evaluated increases in both the total dose and dose intensity of cisplatin or carboplatin while other drugs in the various combination regimens remained unchanged [65, 66, 69, [74] [75] [76] . Only two of these trials demonstrated a significant improvement in median survival. The larger of the two positive studies by Kaye et al. administered cisplatin 50 or 100 mg/m 2 every three weeks for six cycles in combination with cyclophosphamide 750 mg/m 2 . A significant improvement in MS (28.5 months vs. 17.25 months) was seen in favour of the higher dose arm [66] . Long-term follow-up to four years demonstrated this trend for improved survival decreased after two years but continued to remain significant (32.4% for high-dose arm, 26.6% for the low-dose arm at four years) [67] . The authors suggest this represents a delay in emergence of resistant cells rather than an actual cure. Something that may account for the differences in outcome between this study and the other trials is that more patients with less bulky and early stage disease were treated by Kaye et al. suggesting a possible group in which there might be a greater impact of increases in dose intensity. Importantly however, up to one third of patients in the higher dose arm discontinued treatment due to toxicity, leading the authors to recommend a compromise dose of 75 mg/m 2 of cisplatin rather than the 100 mg/m 2 , to balance toxicity with any survival benefit. The negative study by Conte compared cisplatin 100 mg/m 2 to 50 mg/m 2 given day 1 every 28 days (doubling the dose intensity and total dose) in combination with fixed doses of epirubicin (60 mg/m 2 ) and cyclophosphamide (600 mg/m 2 ). There was no signifi- Abbreviations: C -cyclophosphamide; E -epirubicin; P -cisplatin; Cbcarboplatin; A -adriamycin; RDI -relative dose intensity (planned); TDtotal dose; RR -response rate; MS -median survival. a Planned relative dose intensity.
Significant /"-value.
cant improvement in either response rate (57.5% vs. 61.1%), progression-free survival (18 vs. 13 months), or overall survival (29 vs. 24 months) for the high-dose vs. low-dose arm, however the survival trend was apparently in favour of the HD arm [65] .
Of the four studies [70] [71] [72] [73] , where only the dose intensity of platinum compounds was changed and the total dose kept constant, one study showed improved survival [70] . This trial is published only in abstract form, so details about patient characteristics are limited. The largest study of this type, conducted by the GOG, varied not only the dose intensity of cisplatin but also that of cyclophosphamide and included 485 patients with suboptimally debulked disease [71] . Patients received either cisplatin 50 mg/m 2 or 100 mg/m 2 in combination with cyclophosphamide 500 mg/m 2 or 1000 mg/m 2 given every three weeks for eight cycles in the standard-dose arm or for four cycles in the dose intense arm. There was no improvement in response rate or median survival, however there was more toxicity in the dose intensive arm which led many patients to discontinue treatment before the planned four cycles. Only one study varied the total dose of a single-agent platinum compound while maintaining a constant dose intensity [77] . No survival difference was detected despite a 35% increase in total dose.
With only 3 positive trials out of 11, the effect of augmenting the total dose or dose intensity within the range achievable without growth factor or PBSC support appears minimal if it exists at all. Two of the positive studies [69, 70] have very small patient numbers. In the third positive study by Kaye the low-dose arm did not do as well as would be expected, and is inferior to the low-dose arm in the trial by Conte, making one question the actual degree of benefit from increasing doses. Two recent editorials have examined data from all of these trials and concluded that there is no evidence of a meaningful platinum dose effect existing in the dose ranges examined [78, 79] .
High-dose chemotherapy in advanced ovarian cancer
Many feel that, regardless of the results of the randomized trials described above, the true test of the value of HDCT in ovarian cancer will occur only after drug doses are increased to at least five times standard. Several phase I and II trials of high-dose therapy using stem-cell support have been carried out in ovarian cancer [reviewed in 80]. To date no randomized data are available. As already noted in the case of breast cancer, alkylating agents and carboplatin are the most commonly escalated agents since they are active in the disease, have myelosuppression as their major dose limiting effect and have been shown to be synergistic when combined [82] . Unfortunately many of the non-randomized studies reported to date have had small patient numbers, contain mixtures of platinum sensitive and resistant disease and tested a multitude of different regimens making interpretation of results difficult. We will focus our attention on some of the studies with longer follow-up and/or larger patient numbers.
As with most malignancies, new therapies are tested first in relapsed or refractory disease. A small study by Shpall combined high-dose cyclophosphamide (1875 mg/m 2 daily for 3 days) with thiotepa (300 mg/m 2 x 1 dose) and intraperitoneal cisplatin (90 mg/m 2 over 3 days) in 12 patients with bulky advanced cisplatin refractory disease [83] . Although a pathologic partial response of 75% was obtained, median response duration was only six months. There were three toxic deaths and of the nine patients surviving high-dose therapy, six died at a median of nine months after treatment. Stiff et al. have recently reported results in 100 patients who had undergone high-dose therapy with various conditioning regimens in both platinum sensitive and resistant disease [84] . In multivariate analysis they found that younger age, disease bulk < 1 cm and platinum sensitivity at the time of transplant were the best predictors of overall survival, with bulk being most important. For patients included in the review with resistant disease a response rate of 81% was achieved (50% clinical CR). Unfortunately, the median progression-free and overall survival was short: only 5.4 months and 9.6 months, respectively.
While the response rate appears higher than that achievable with single-agent conventional-dose paclitaxel in refractory patients (33%) the median response duration is similar (four months) [85] . Median survival for platinum sensitive patients was 23 months [84] . Subgroup analysis demonstrated that if residual disease at the time of transplant was less than 1 cm, patients with platinum sensitive or resistant disease had favourable median survivals (28 months). If residual disease was greater than 1 cm in refractory patients their outcome was no different than that expected with standard salvage regimens (median survival 8.6 months) [84] . Because HDCT does not appear effective in advanced refractory patients, subsequent trials have focussed their attention on patients with earlier less resistant and less bulky disease, similar to the evolution in other tumor types in which HDCT is being evaluated.
High-dose therapy in primary ovarian cancer treatment has been given either after debulking surgery and standard conventional-dose cisplatin containing chemotherapy or as part of the initial chemotherapy plan. A few of the phase II studies reporting survival results are presented in Table 6 [86] [87] [88] [89] . Legros et al. have the largest series and the longest follow-up [86] . Their trial, involving 50 patients with both optimally (62%) and suboptimally debulked (46%) disease, reported a progression-free survival (PFS) of 2.5 years and an overall survival of 5 years (median). The high-dose regimens consisted of either single-agent melphalan or a combination of carboplatin and cyclophosphamide. One toxic death from to cardiac failure occurred after transplant. Compared to the most active front-line regimen (cisplatin + paclitaxel) where median PFS of 1.5 years and a median survival of 3.2 years is seen, high-dose therapy seems promising [90] . However, one must keep in mind the difficulties comparing different studies and the influence of selection bias in those high-dose trials where only responding patients are included. These trials have shown, however that high-dose therapy in this disease is feasible and can be administered with acceptable toxicity and good response rates. What is not yet known is how this compares to the best standard treatment. Several randomized trials giving HDCT as consolidation or as part of primary therapy are ongoing ( Table 7) . The fact that many are experiencing accrual difficulties suggests collaborative efforts between groups would be wise if this approach is ever to be successfully tested. Until results of such comparative studies are known, HDCT in ovarian cancer remains experimental.
Small-cell lung cancer
The currently accepted standard treatment for smallcell lung cancer (SCLC) in both limited (LD) and extensive (ED) disease, is combination chemotherapy. Commonly used regimens include CAV (cyclophosphamide, adriamycin and vincristine) and EP (VP-16 and cisplatin). In limited disease such treatment results in response rates up to 85%-90% (50%-60% CR) and median survival of 14-16 months compared to only 3 months without any therapy. Extensive disease has similarly high response rates of 75%-85% (15%-25% CR) but a shorter median survival of 7-11 months versus 5 weeks without any treatment. Despite these high response rates and gains in median survival, most patients will still relapse with resistant disease with a five-year survival of 2%-8% for limited stage disease and only rare two-year survivors for extensive stage SCLC [91] . Although survival has been significantly increased in this disease by combination chemotherapy, as noted most patients relapse and eventually die of their disease. Various manipulations of current treatment regimens have improved results slightly. Alternating regimens of CAV and EP, in a test of the Goldie-Coldman hypothesis, may be associated with a slightly greater survival advantage in limited stage disease than when either combination is given alone [92] . Timing of the administration of thoracic radiation in limited SCLC has also been shown to be an important determinant of outcome [93] . The gains in terms of survival however are still quite modest and overcoming resistance in this tumor remains a challenging task. New agents are constantly being evaluated and promising ones are in the early stages of being tested in combination with standard regimens [94] . In addition to the approach of adding new drugs, some investigators have evaluated increased doses of standard chemotherapy agents. Trials assessing the impact of increasing dose intensity as well as HDCT will be discussed.
One method of increasing the dose intensity of chemotherapy is to administer drugs more frequently, for example at weekly intervals. Early phase II studies examining four-drug regimens, with weekly administration showed promising response rates (RR) and median survival (MS) in both ED and LD patients [95, 96] . However, randomized comparison of these dose intense regimens to conventional treatment failed to demonstrate any superiority of the experimental arm (Table 8 ). In the study by Murray et al., CODE was compared to the alternating regimen of CAV/EP in ED patients [97] . The total dose between regimens was essentially the same, however the dose intensity for all drugs in the CODE arm was at least twice that of the standard regimen. A significant difference in response rate was seen between the two arms (64% vs. 53% for CODE vs. CAV/EP) but this did not translate into a survival benefit (12.7 months vs. 11.5 months for CODE vs. CAV/EP). The CODE arm had a higher number of deaths (9.1% vs. 1%) and was more toxic. Since no growth factors were used in that study, Furuse et al. compared the same regimens adding G-CSF to the CODE arm in an attempt to reduce toxicity and deliver more drug. Despite the use of growth factors there was no significant difference in response rate or median survival, and both arms had neutropenia as their dose limiting toxicity [98] . Another trial compared an alternating regimen consisting of seven active drugs to standard dose CAE [99] . The only significant result seen was in the response rate achieved in limited disease with the seven-drug regimen (84% vs. 62%). No differences were seen in median or two-year survival in the study population or in the subgroups of limited or extensive disease patients. One trial showed a positive impact of weekly chemotherapy on survival compared to a monthly regimen (100) . In this study, the median survival for patients randomized to CAV/PVP given in monthly alternating cycles was significantly less than for CAV/PVP given as a weekly regimen (9.6 months versus 17.7 months). The study has been presented only in abstract form, however, and does not describe the patient group studied. It is noteworthy that the 'standard' arm in this trial was given in a less intensive manner than usual (every four weeks rather than every three weeks) [100] . In general then, most studies have not shown improved results by administration of weekly chemotherapy as compared to more conventional regimens. Dose intensity can also be augmented by increasing the dose of drugs given per cycle. It has been postulated that giving more intensive chemotherapy in the first few cycles might help prevent the emergence of resistance. There are seven randomized studies testing this hypothesis [reviewed in 94] . Five early studies, comprised of mixed populations of LD and ED patients examined regimens not commonly used today. One of these trials showed a slight survival advantage for the more dose intensive arm in the subset of LD patients [94] . Two of the more recent trials (Table 8) employed cisplatin based chemotherapy [101, 102] . Only the study by Arriagada in LD patients showed improved survival [101] . All 105 randomized patients received the same doses of doxorubicin and etoposide while cyclophosphamide and cisplatin doses were increased in the higher dose arm for the first cycle of treatment only resulting in a 25% increase in cyclophosphamide and 20% increase in cisplatin doses. In subsequent cycles patients in both arms received the same chemotherapy. All patients received chest radiotherapy. There was no difference in complete response rates between groups (67% HD, 54% LD). Patients who received the higher doses of cyclophosphamide and cisplatin in the first cycle of treatment had a significantly longer DFS at two years (28% vs. 8%, P = 0.02) and overall survival at two years (43% vs. 26%, P = 0.006). A second study randomized 90 patients with ED to receive either high-dose EP (etoposide, cisplatin) or standard dose EP [102] . There were no significant differences between the high-dose and standard-dose arms in terms of response rate (86% vs. 83%), median response duration (7 months vs. 6.9 months), and median survival (11.4 months vs. 10.7 months). These results seem to indicate that if there is benefit from increasing the dose intensity of currently available drugs, it is limited disease patients who are most likely to demonstrate this. As was shown in other tumor types, there may be a threshold dose which is necessary to achieve optimal antitumor effects and doses below 'standard' may give inferior outcomes. Whether increases beyond these doses will be able to overcome resistance has not been proven. Consistent with the variable results described, a meta-analysis of dose-intensity of chemotherapy regimens in SCLC found no consistent correlations between DI and outcome in either LD or ED SCLC for the regimens CAV/CAE/CAVE or EP [103] . Some have tried to maintain or increase dose intensity by administering G-CSF or GM-CSF with chemotherapy [104] [105] [106] . When G-CSF was added to standard dose CAE, infectious complications were found to be less frequent in the G-CSF arm but the dose intensity of this arm was only 7%-9% higher than the non-G-CSF arm. There was no difference in median survival between treatment groups [104] . Two other studies using hematopoietic growth factors to increase the dose intensity of chemotherapy failed to show any reduction in infectious complications and no improvement in survival for the more dose intensive arm [105, 106] . These data would suggest that, at least for the regimens used, dose intensification with the addition of growth factors does not result in higher rates of response and survival or lower rates of infectious complications. Doses of these drugs were actually increased by only 12%-25%, so one could still argue that improvements in outcome might be achieved in SCLC by administering even higher doses with stem-cell support. Only one randomized trial has been reported comparing high-dose chemotherapy with stem-cell support to conventional-dose chemotherapy [107] . Of the 101 patients entered, 54 had LD and 47 had ED. All patients received an induction regimen consisting of three cycles of methotrexate (40 mg both given on days -6 to -3 , followed by rescue with autologous bone marrow. The conventional arm received one cycle of cyclophosphamide (750 mg/m 2 on day 1), etoposide (20 mg/m 2 orally days 1-5) and BCNU (60 mg/m 2 on day 1). None of the patients received thoracic radiotherapy. The CR rate for all patients after induction chemotherapy was 39%. This increased to 79% after HDCT. There was no change in CR rate in the control arm. The HDCT group had a significant improvement in relapse-free survival (7 months vs. 2.5 months) vs. the conventional treatment group, and, although median survival was observed to be longer (17 months vs. 13.5 months), the difference was not significant. An 18% mortality rate was associated with the HDCT group, with the deaths occurring during the period of aplasia. The longest survivor who received HDCT died of acute leukemia 263 weeks after transplant. Patients in both groups tended to relapse at the primary tumor site. The study was small and therefore may not have had the power to detect small but significant differences in survival. Despite this, however, results in the HDCT group are similar to that achieved with the conventional chemotherapy regimens used today [91] . Many other phase I-II studies have been completed and are reviewed by Elias [108] .
As was the case with both breast and ovarian cancer, HDCT appears more promising in earlier stage disease where resistance is likely to be less and where the patients may be better able to tolerate treatment. However, the value of high-dose therapy still needs to be determined in this disease using newer regimens and other measures to decrease treatment related mortality (PBSC and growth factors). It seems that it is in the patients with LD where HDCT, if it is going to work, will demonstrate a benefit. For now it should be considered an experimental treatment.
Conclusions
For each of the three solid tumors examined: breast, ovary and small-cell lung cancer, solid evidence to advocate the use of HDCT in standard patient management is lacking. Randomized data comparing 'standard' therapy to HDCT, where it exists, is unconvincing. In breast cancer eight randomized trials (three in metastatic disease and five in adjuvant setting) have been reported, largely in preliminary abstract form. Although several of the trials are small and thus underpowered to detect differences in outcome of 10%-20%, only two of the eight trials have been positive. Both were conducted by Bezwoda who utilized a strategy of initial high-dose treatment, rather than the consolidation approach employed in other studies and by practitioners when treating non-protocol patients. Clearly, these data do not support the routine use of HDCT in any setting in breast cancer. Several ongoing trials have yet to be reported so no new studies are needed with the exception, perhaps, of a trial to explore the strategy of initial high-dose treatment.
In small-cell lung cancer one small trial suggests there may be an improvement with HDCT but a relapse free survival advantage did not translate into improved overall survival. Thus there is insufficient evidence to change practice. No randomized data are available in ovarian cancer to support routine HDCT.
Selection bias may account for favourable results in uncontrolled studies in ovary, breast and SCL cancers, as several authors have pointed out by reviewing outcomes of HDCT 'candidates' who received only standard therapy. Adequately powered, properly controlled studies in primary and metastatic breast cancer as well as front-line ovarian cancer are ongoing and will provide the data needed to determine if and when high-dose therapy should become the new standard of care.
In the meantime, it will be useful to consider the evolution of this therapeutic approach and try to understand, why, in the absence of good evidence, HDCT appears to be enjoying widespread and growing use. Is it related to disparate views on the strength of evidence? Differing beliefs about the likely truth of the high-dose/ dose intensity hypothesis? Differing public pressures to adopt new (and presumable therefore better) therapies? It is important to explore these issues since it will teach us more about how and why new treatments are adopted. Had substantial numbers of the many patients receiving HDCT as standard care been enrolled on randomized studies, the debate about its role in management of common solid tumors would likely now be resolved.
